

FACILE SYNTHESIS AND PHOTOLUMINESCENCE PROPERTIES OF NOVEL HEPARIN/CaMoO₄: Yb, Er BIOCOMPOSITES

Y. GAO^{a,b*}, Q. WU^a, X. LIN^a, X. ZHANG^a

^aCollege of Ocean, Hainan University, Haikou 570228, China

^bKey Laboratory of Tropical Biological Resources of Ministry of Education, Hainan University, Haikou 570228, China

Novel heparin/CaMoO₄: Yb, Er biocomposites (heparin/CaMoO₄) are synthesized by a facile hydrothermal routes with Na₂EDTA as a chelating agent. XRD, SEM, and photoluminescence (PL) spectra have been used to characterize the size, morphology and photoluminescence spectrum of the heparin/CaMoO₄. Heparin and CaMoO₄ nanoparticles are shaped into a homogeneous biocomposites. The latent photoinduced electrons transfer between heparin and CaMoO₄ nanocrystals weaken upconversion (UC) luminescence intensity of heparin/CaMoO₄, but the aqueous dispersion of heparin/CaMoO₄ still present naked eye-visible green luminescence under a 980 nm laser in the power density only about 50 mWcm⁻². Obtained heparin/CaMoO₄ biocomposites will paves the way for promising applications in biomedical fields as luminescent bioprobes.

(Received March 27, 2017; Accepted July 1, 2017)

Keywords: heparin; CaMoO₄; biocomposites; chemical synthesis; photoluminescence

1. Introduction

Heparin is a linear polysaccharide which consists of 1-4 linked disaccharide repeating units of uronic acid and glucosamine residues. Heparin plays an important role in many biocomposites via its interaction with various proteins, and hydrogels and nanoparticles comprising heparin exhibit attractive properties, such as anticoagulant activity, growth factor binding, and antiangiogenic and apoptotic effects, making them great candidates for emerging applications.[1] Many kinds of functional nanoparticles, such as Au, Fe₃O₄, and SiO₂ nanoparticles have been successfully combined with heparin or its derivatives.[2-4] The emergence of novel biocompatible luminescent probes and multiphoton fluorescence microscopy has had a significant impact on imaging cells, both in vivo and in vitro.[5] However, studies on the biocomposites of UC luminescent nanocrystals and heparin, which generates superior luminescence and well biocompatible performance by combining the advantages of both, are still few.

Recently, lanthanide doped upconversion nanoparticles (UPNP) such as, NaYF₄: Yb, Er, CaMoO₄: Yb, Er, represent a new generation of luminescent probes.[6, 7] These nanoparticles have a unique ability to upconvert near-infrared radiation (NIR), to visible or ultraviolet light.[5, 8] Other distinct advantages, such as minimal background autofluorescence and photobleaching under near infrared (NIR) excitation, high room-temperature quantum yields and long luminescence life time result in a fact that Ln³⁺-doped UPNP are regarded as an ideal fluorescence labeling material for potential applications in many fields, especially in biomedicine.[9] The functionalization of these nanoparticles with naturally occurring polysaccharides, which play an important role in protein and cell interactions, tissue regeneration, drug delivery, cancer diagnosis and treatment, may provide a considerable potential in a variety of bioimaging applications.[4, 10] Therefore, it's very necessary to develop a facile way for the biocomposites of UPNP and heparin with good luminescence intensity and excellent biocompatibility.

* Corresponding author: gaoyong_1997@sina.com

In this work we report on the very straightforward synthesis of advanced biocompatible imaging nanoprobes, heparin/CaMoO₄. Our design involves a continuous process. In the 90 °C water, a stoichiometric amount of rare earth compound solution, Na₂EDTA solution, and (NH₄)₆Mo₇O₂₄ solution are mixed one by one. A half hour later, the mixture is mixed with heparin sodium solution, and the hydrothermal process at 180 °C is carried out. The morphology and microstructure of heparin/CaMoO₄ were investigated by X-ray powder diffraction (XRD) and scanning electron microscopy (SEM). The influence of adding quantity of heparin for the UC luminescence of heparin/CaMoO₄ is investigated. The possible energy transfer from the UPNS to the energy receptor in heparin substrate is also explored.

2. Experimental and Characterization

2.1 Synthesis of heparin/CaMoO₄ nanocomposite

All chemicals were used directly without further purification. In a typical procedure, 16 ml of 0.1M Ca(NO₃)₂, 3.6 ml of 0.1M Yb(NO₃)₃, and 0.4 ml of 0.1M Er(NO₃)₂ were prepared in a beaker with 90 °C distilled water by constant stirring with magnetic stirrer. And then 25 ml of 0.1 M Na₂EDTA solution was added into previous mixture. In a separate beaker, 20 mM (NH₄)₆Mo₇O₂₄ was prepared in 95 °C distilled water. After that, (NH₄)₆Mo₇O₂₄ solution was added into previous mixture under continuous stirring. The pH of the resulting solution was adjusted by aqueous ammonia solution. A half hour later, the mixture are mixed with heparin sodium solution (1.5 wt%). A half hour later, the mixture was transferred to Teflon-lined autoclave and heated at 180 °C for 2 h. Obtained sample were purified by centrifugation, washed with DI water and dried under vacuum.

2.2 Characterization

XRD measurements were performed on a Bruker D8 Advance X-ray diffractometer with Cu K α ($\lambda = 1.5418 \text{ \AA}$) radiation. The SEM micrographs were obtained using scanning electron microscopy (SEM, S-3000N, Hitachi). The Transmission electron microscopy (TEM) and high-resolution transmission electron microscopy (HRTEM) were characterized by a JEOL 2100 running at an accelerating voltage of 200 kV. Fourier-transform infrared spectrometry (FT-IR) was recorded on a Bruker TENSOR27 IR spectrophotometer, and the sample were pulverized with KBr and pressed into pellets. The thermo-gravimetric analysis (TGA) was carried out with a SDT Q600 analyzer with a heating rate of 10 °C min⁻¹, and the sample was measured in a corundum crucible in nitrogen atmosphere from room temperature to 510 °C. The photoluminescence spectra were recorded using an F-7000 spectrofluorimeter (Hitachi, Japan) with an external 980 nm laser as the excitation source.

3. Results and discussion

To obtain the structure information about as-prepared heparin/CaMoO₄ biocomposites, powder XRD characterization is conducted. For comparing and analyzing the influence of heparin, CaMoO₄:Yb,Er nanocrystals without heparin are prepared by a hydrothermal route. As shown in Fig. 1, the peak positions and intensities of CaMoO₄:Yb,Er nanocrystals without heparin agree well with the data reported in the JCPDS standard card (77-2240) of pure tetragonal CaMoO₄ crystals.[11] For obtained heparin/CaMoO₄ biocomposites, it is clear that heparin/CaMoO₄ biocomposites contains XRD signals of both heparin and a standard sample of CaMoO₄ crystals, which indicating that biocomposites retains the crystal structures of both material. Several strong diffraction peaks in the XRD patterns observed at $2\theta = 18.5^\circ, 29.1^\circ, 31.5^\circ, 34.6^\circ, \text{ and } 58.6^\circ$, can be assigned to the (101), (112), (004), (200), and (312) reflections of CaMoO₄:Yb,Er nanoparticles, respectively. [11] Also, a weaker characteristic peak of heparin located at about 23° in the XRD patterns of heparin/CaMoO₄ reveal that CaMoO₄:Yb,Er nanoparticles attached with heparin sheets destroy the nature orientation of heparin [12].




Fig 1. XRD patterns of as-prepared $\text{CaMoO}_4:\text{Yb,Er}$ nanocrystals, heparin/ CaMoO_4 biocomposites, and heparin sodium [red vertical bars at the bottom are standard tetragonal phase CaMoO_4 crystal (JCPDS 77-2240)].




Fig 2. SEM images of obtained heparin/ CaMoO_4 biocomposites.

SEM images show the direct morphology of obtained heparin/ CaMoO_4 biocomposites. As shown in Fig. 2, heparin and $\text{CaMoO}_4:\text{Yb, Er}$ nanocrystals have been constructed to be a homogeneous biocomposites, and the biocomposites are spherical in shape with a mean diameter of approximately 150 nm. Also, the particles are reasonably uniform in size. Higher magnification SEM image (Fig. 2 b) shows the surface of heparin/ CaMoO_4 is unsmooth. And the heparin/ CaMoO_4 is also slightly crannied. The $\text{CaMoO}_4:\text{Yb, Er}$ nanocrystals might be anchored on the surface of heparin structure, and then both are interlaced with each other. Finally, approximately spherical biocomposites are obtained.




Fig 3. FT-IR spectra of as-prepared $\text{CaMoO}_4:\text{Yb,Er}$ nanocrystals, heparin/ CaMoO_4 biocomposites, and heparin sodium

Further evidence for the information on the chemical characteristics and surface structure of heparin/CaMoO₄ biocomposites was obtained by FT-IR analysis. As shown in Fig 3, two strong peaks at 3452 cm⁻¹ and 1628 cm⁻¹ are assigned to the strong hydroxyl vibration from H₂O in heparin and the amino group (-NH₂). And other four peaks at 2931 cm⁻¹, 1424 cm⁻¹, 1236 cm⁻¹, and 1033 cm⁻¹ are from the stretching vibration of C-H, the deformation vibration of -CH₃, asymmetrical stretching vibration of S=O and the symmetrical stretching vibration of -SO₃, respectively.[13] For CaMoO₄:Yb,Er nanocrystals, it is clear that the strong peak at 3460 cm⁻¹ (ν_{O-H}) comes from the water molecules adsorbed on CaMoO₄:Yb,Er nanocrystals and the peak at 847 cm⁻¹ represents the typical Mo-O anti-symmetric stretching vibrations in the [XO₄]²⁻ tetrahedron groups.[14] However, for obtained heparin/CaMoO₄ biocomposites, the weakened peak at 1642 cm⁻¹ and the enhanced peak at 1401 cm⁻¹ and 1116 cm⁻¹ imply the coordination interaction between the heparin net structure and the Na₂EDTA chelated CaMoO₄:Yb,Er nanocrystals, while the disappearance of the 847 cm⁻¹ peak further proves that the CaMoO₄:Yb, Er nanocrystals are anchored on the surface of heparin net structure in the spherical biocomposites.




Fig 4. TGA curves of as-prepared CaMoO₄:Yb,Er nanocrystals, heparin/CaMoO₄ biocomposites, and heparin sodium

The composition changing and different components of CaMoO₄:Yb,Er nanocrystals, heparin/CaMoO₄ biocomposites, and heparin sodium are investigated by TGA analysis. As shown in Fig 4, TGA trace of CaMoO₄:Yb,Er nanocrystals shows little weight loss, which is about 1.2% below 500 °C. Comparing with the CaMoO₄:Yb,Er, heparin sodium shows much lower thermal stability. The first one, at range from 50 to 125 °C, is attributed to the evaporation of water. Heparin presents in its structure groups such as carboxylate (-COO-) and sulfonate (-OSO₃-), which are highly hydrophilic and could strongly interact with water molecules through dipole-dipole or ion-dipole forces.[15] The main mass loss takes place around 200–400 °C and is ascribed to the decomposition of labile oxygen functional groups present in the material. There is also a steady mass loss (~8%) over the whole temperature range between 400 and 500 °C, which can be assigned to the removal of more stable oxygen functionalities.[16] And the overall mass loss of heparin is 56%. The TGA curves of heparin/CaMoO₄ biocomposites is similar to heparin. The measurement of the sample mass below 500 °C showed that the overall mass loss of heparin/CaMoO₄ biocomposites is 25%. It is suggested that the incorporation of CaMoO₄ nanoparticles into the biocomposites is about 45%. Furthermore, absent mass loss of heparin/CaMoO₄ biocomposites between 400 and 500 °C may be due to that CaMoO₄ nanoparticles into the biocomposites prevent the removal of stable oxygen functionalities.




Fig 5. Photoluminescence spectra of $\text{CaMoO}_4:\text{Yb,Er}$ nanocrystals, heparin/ CaMoO_4 biocomposites, and heparin sodium

Under the 980 nm laser excitation, there is no UC luminescence for the pure heparin sodium. However, the $\text{CaMoO}_4:\text{Yb,Er}$ nanocrystals emit brighter green luminescence than heparin/ CaMoO_4 biocomposites. As depicted in Fig 5, in the wavelength region of 450-700 nm, the three emission peaks of the as-prepared nanocrystals at 517, 536, and 651 nm are assigned to the $^4\text{H}_{11/2}$ to $^4\text{I}_{15/2}$, $^4\text{S}_{3/2}$ to $^4\text{I}_{15/2}$, and $^4\text{F}_{9/2}$ to $^4\text{I}_{15/2}$ transitions of Er^{3+} , respectively. Under 980 nm excitation, Er^{3+} absorbs one photon and its groundstate ($^4\text{I}_{15/2}$) electron is excited to the $^4\text{I}_{11/2}$ level. A second photon promotes the electron to the $^4\text{F}_{7/2}$ level. The excited electron decays first nonradiatively to $^2\text{H}_{11/2}$, $^4\text{S}_{3/2}$, and $^4\text{F}_{9/2}$ levels. When it decays further to the ground state, UC emission occurs.[17] As shown in the inset of Fig 5, under excitation at 980 nm in a power density only about 50 mWcm^{-2} , heparin/ CaMoO_4 biocomposites dispersed in water show strong green UC luminescence.




Fig. 6. Photoluminescence spectra of heparin/ CaMoO_4 biocomposites prepared with different amount of heparin sodium

The PL spectra of heparin/ CaMoO_4 biocomposites prepared with different amount of heparin sodium are shown in Fig. 6. With the increase of the ratio of heparin sodium, the UC luminescence intensity of heparin/ CaMoO_4 biocomposites begins to decrease. This may be due to that heparin sodium into heparin/ CaMoO_4 biocomposites could decrease the UC luminescence intensity of biocomposites. Hence, in the following paragraph, the possible electronic transmissions behavior of photoinduced electron in heparin/ CaMoO_4 biocomposites is discussed in detail.




Fig 7. Schematic of the possible photo-induced electron transfer mechanism in heparin/CaMoO₄ biocomposites

As illustrated in Fig 7, the CaMoO₄:Yb,Er nanocrystals are anchored on the net structure of heparin by chemical bonding, the close distance enables efficient energy transfer from CaMoO₄:Yb,Er nanocrystals to the energy receptor in heparin substrate.[17] The electrons in Yb³⁺ are first excited, and then the energy transferred to Er³⁺ further induces the electron excitation, as well as other multiphoton processes in Er³⁺. The hexamylose or octamylose skeleton, the oxygen-containing functional group, and sulfite containing functional group of heparin/CaMoO₄ biocomposites are high-efficiency energy acceptors.[18] So Er³⁺ transfers a fraction of energy to the nearby heparin via the fluorescence resonance energy transfer (FRET) or charge transfer (CT) process instead of the normal nonradiative relaxation of ²H_{11/2} to ⁴I_{15/2}, ⁴S_{3/2} to ⁴I_{15/2}, and ⁴F_{9/2} to ⁴I_{15/2}. [19] Therefore, with the increase of heparin sodium, energy transfer and luminescence quenching may enhance, so the UC luminescence of heparin/CaMoO₄ biocomposites is weaker.

4. Conclusion

In the present work, green-emitting heparin/CaMoO₄ biocomposites are successfully fabricated by a facile hydrothermal method with Na₂EDTA as a chelating agent. And the structure, morphology and fluorescence properties of the heparin/CaMoO₄ biocomposites are studied. Obtained heparin/CaMoO₄ biocomposites are microspheres with a mean diameter of approximately 150 nm. Heparin into heparin/CaMoO₄ biocomposites could decrease the UC luminescence intensity of biocomposites. However, the dispersion of heparin/CaMoO₄ shows bright green luminescence under excitation at 980 nm in a power density only about 50 mWcm⁻².

Acknowledgements

This work was supported by the Innovative Project of Hainan Province in 2015, and the Practice & Innovation Projects of Hainan University in 2016 for financial support. The Instrumental Analysis Centre of Hainan University is also acknowledged here.

References

- [1] Y. K. Liang, K. L. Kiick, *Acta Biomaterialia* **10**, 1588 (2014).
- [2] S. Ma, Y. Chen, F. Jie, J. Liu, X. Zuo, X. Chen, *Analytical Chemistry* **88**, 10474 (2016).
- [3] T. Y. Liu, L. Y. Huang, S. H. Hu, M. C. Yang, S. Y. Chen, *J Biomed Nanotechnol* **3**, 353 (2007).
- [4] N. Bogdan, E. M. Rodríguez, F. Sanzrodríguez, et al. **4**, 3647 (2012).
- [5] Y. Liu, D. Tu, H. Zhu, X. Chen, *Chemical Society reviews* **42**, 6924 (2013).

- [6] M Haase, H Schäfer, *Angewandte Chemie International Edition* **50**, 5808(2011).
- [7] H. N. Luitel, R. Chand, T. Torikai, M. Yada, T. Watari *Rsc Adv* **5**, 17034 (2015).
- [8] A. Gnach, T. Lipinski, A. Bednarkiewicz, J. Rybka, JA. Capobianco, *Chemical Society reviews* **44**, 1561 (2015).
- [9] F. Wang, X. G. Liu, *Chemical Society reviews* **38**, 976 (2009).
- [10] X. Fernandez-Busquets, *Future Med Chem* **5**, 737 (2013).
- [11] J. Liu, K. Liu, H. Gao, Y. Liu, C. Yang, Z. Liu, *J Mater Sci-Mater El* **26**, 3380 (2015).
- [12] D. M. Zhao, Y. X. Wang, Z. Y. Chen, RW. Xu, G. Wu, DS. Yu, *Biomedical materials* **3**, 025016 (2008).
- [13] G. V. Kumar, CH. Su, P. Velusamy, *Materials Letters* **180**, 119 (2016).
- [14] T. Thongtem, S. Kungwankunakorn, B. Kuntalue, A. Phuruangrat, S. Thongtem, *J Alloy Compd* **506**, 475 (2010).
- [15] M. Baican, E. Paslaru, EG. Hitruc, C. Vasile, *Dig J Nanomater Bios* **6**, 1053 (2011).
- [16] M. M. Sk, C. Y. Yue, RK. Jena *Rsc Adv* **4**, 5188 (2014).
- [17] C. Q. Yang, J. Liu, L. Y. Ma, A. J. Li, Z. X. Liu, *Materials Research Bulletin* **84**, 283 (2016).
- [18] C. Q. Yang, L. Y. N. Ma, SN Wu, et al. *J. Mater Sci-Mater El* **27**, 11720 (2016).
- [19] W. Wei, T He, X Teng, et al. *Small* **8**, 2271 (2012).